Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Shaman Pharmaceuticals |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002186 |
To evaluate the safety of topically applied SP-303 gel and to compare the efficacy of SP-303 gel in combination with acyclovir, relative to acyclovir alone, for the treatment of recurrent Herpes Simplex Virus (HSV) 1 and 2 infections, affecting the genital, perianal and neighboring areas, in patients with AIDS.
Condition | Intervention |
---|---|
Herpes Simplex HIV Infections |
Drug: Crofelemer Drug: Acyclovir |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind, Safety Study |
Official Title: | Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS) |
Estimated Enrollment: | 400 |
This trial is a double-blind, multicenter, placebo-controlled clinical trial. Participants are randomized to topical 15% SP-303 gel and oral acyclovir or to matching topical placebo gel and oral acyclovir. At presentation, patients are stratified by total lesion area within each treatment group. SP-303 or matching placebo is topically applied three times a day until all lesions are reepithelialized or for 14 days, whichever occurs earlier. Acyclovir is administered by mouth each day, three times a day, until all lesions are reepithelialized or for 14 days, whichever occurs earlier. Patients are evaluated for lesion healing and adverse events 3 times per week during the treatment period. The primary efficacy endpoint will be complete lesion healing and the primary analysis will be time to complete healing.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
Patients with the following prior conditions are excluded:
Previous enrollment in this study.
1. Treatment with another medication (topical, oral, or intravenous) with known anti-HSV activity within the past 5 days.
Required:
Unchanged antiretroviral therapy for the 2 weeks prior to study.
Study ID Numbers: | 270A, 96-867-DE |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002186 |
Health Authority: | United States: Food and Drug Administration |
AIDS-Related Opportunistic Infections Herpes Simplex Drug Therapy, Combination Acyclovir |
Antiviral Agents Gels SP 303 |
Herpes Simplex Opportunistic Infections Sexually Transmitted Diseases, Viral Skin Diseases Acquired Immunodeficiency Syndrome Immunologic Deficiency Syndromes Recurrence Herpesviridae Infections |
Virus Diseases Skin Diseases, Infectious Acyclovir HIV Infections AIDS-Related Opportunistic Infections Sexually Transmitted Diseases DNA Virus Infections Retroviridae Infections |
Skin Diseases, Viral Anti-Infective Agents Communicable Diseases RNA Virus Infections Slow Virus Diseases Immune System Diseases |
Therapeutic Uses Lentivirus Infections Infection Antiviral Agents Pharmacologic Actions |